Overview

A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

Status:
RECRUITING

Trial end date:
2028-08-31

Target enrollment:

Participant gender:

Summary

This Phase III, randomized, open label, multicenter study will evaluate the efficacy and safety of SIM0270 combined with everolimus compared to physician's choice of treatment in subjects with ER+/HER2- locally advanced or metastatic breast cancer who have had previous treatment with CDK4/6 inhibitor.

Phase:

PHASE3

Details

Lead Sponsor:

Jiangsu Simcere Pharmaceutical Co., Ltd.

Collaborator:

Nanjing Zaiming Pharmaceutical Co., Ltd.

Treatments:

Everolimus
exemestane
Fulvestrant